Reappraisal of giant basal cell carcinoma: clinical features and outcomes
Grant, Megan E
Rashed, Andzhela A
Green, Adèle C
AffiliationThe Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.
MetadataShow full item record
AbstractBACKGROUND: Giant basal cell carcinoma (GBCC) is a rare subgroup of basal cell carcinomas with a diameter of >5?cm. Current evidence about determining factors is conflicting, suggesting patient neglect, on the one hand, and biologically aggressive behaviour, on the other, with outcomes varying from clearance to death. We aimed to clarify the natural history of GBCC and its response to treatment. METHODS: We extracted information from clinical records of all patients with GBCC treated from 1998 to 2017 in a tertiary oncology hospital in northwest England. Associations between patient and tumour characteristics were investigated, and modes of treatment and outcomes were assessed. RESULTS: In the 20-year study period, 43 patients (median age 76 years; 23 (53%) female), 3 of whom had Gorlin syndrome, were treated for GBCCs. Median diameter was 6.3?cm, and median time to presentation was 5 years. Seven (16%) GBCCs arose from recurrent BCC, while the majority (84%) presented de novo. The size of GBCC was significantly correlated with delay in presentation (p?=?0.03) but not with age or sex. Of 41 patients receiving definitive treatment, 19 GBCCs were treated by excision with ²1?cm margin and none recurred during follow-up, compared with 10 recurrences of 23 treated with photodynamic therapy (PDT), and 1 of 7 recurred after radiotherapy. Two of 43 patients with GBCC (<5%) presented with extensive local invasion, one of whom also had distant metastases, and both died of the disease. CONCLUSION: The majority of GBCCs are not clinically aggressive and respond to conservative surgical treatment with a low risk of recurrence.
CitationOudit D, Pham H, Grecu T, Hodgson C, Grant ME, Rashed AA, et al. Reappraisal of giant basal cell carcinoma: Clinical features and outcomes. J Plast Reconstr Aesthet Surg. 2019 Jun 28.
JournalJournal of Plastic, Reconstructive & Aesthetic Surgery
- Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
- Authors: Roozeboom MH, Aardoom MA, Nelemans PJ, Thissen MR, Kelleners-Smeets NW, Kuijpers DI, Mosterd K
- Issue date: 2013 Aug
- When basal cell carcinomas became giant: an Italian multicenter study.
- Authors: Gualdi G, Monari P, Calzavara-Pinton P, Caravello S, Fantini F, Bornacina C, Specchio F, Argenziano G, Simonetti V, Caccavale S, La Montagna M, Cecchi R, Landi C, Simonacci M, Dusi D, Puviani M, Zucchi A, Zampieri P, Inchaurraga MAG, Savoia F, Melandri D, Capo A, Amerio P
- Issue date: 2020 Mar
- Sequential treatment of giant basal cell carcinomas.
- Authors: Madan V, West CA, Murphy JV, Lear JT
- Issue date: 2009 Oct
- Giant Basal Cell Carcinomas Express Neuroactive Mediators and Show a High Growth Rate: A Case-Control Study and Meta-Analysis of Etiopathogenic and Prognostic Factors.
- Authors: Yazdani Abyaneh MA, Engel P, Slominski A, Ragsdale B, Agag R, Cramer D, Carlson JA
- Issue date: 2017 Mar
- [Why is it important to differentiate trichoblastic carcinomas (CT) from basal cell carcinomas (CBC). About 21 cases].
- Authors: Thomas M, Bruant-Rodier C, Bodin F, Cribier B, Huther M, Dissaux C
- Issue date: 2017 Jun